WO2011017219A1 - Imidazoquinoxalinones et traitement anti-tumoral - Google Patents
Imidazoquinoxalinones et traitement anti-tumoral Download PDFInfo
- Publication number
- WO2011017219A1 WO2011017219A1 PCT/US2010/043927 US2010043927W WO2011017219A1 WO 2011017219 A1 WO2011017219 A1 WO 2011017219A1 US 2010043927 W US2010043927 W US 2010043927W WO 2011017219 A1 WO2011017219 A1 WO 2011017219A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- compound
- heteroaryl
- aryl
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title description 3
- HOFSPGAYXKNFAM-UHFFFAOYSA-N imidazo[4,5-f]quinoxalin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=N1 HOFSPGAYXKNFAM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 37
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 20
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- -1 C-6 haloalkyl Chemical group 0.000 claims description 84
- 125000000217 alkyl group Chemical group 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 45
- 125000002947 alkylene group Chemical group 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical class 0.000 claims description 32
- 125000004429 atom Chemical group 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 24
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 24
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 16
- 125000000732 arylene group Chemical group 0.000 claims description 16
- 125000005549 heteroarylene group Chemical group 0.000 claims description 15
- 101150082854 Mertk gene Proteins 0.000 claims description 14
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 14
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 12
- 208000032839 leukemia Diseases 0.000 claims description 12
- 206010025323 Lymphomas Diseases 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 8
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 6
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 6
- 229960005141 piperazine Drugs 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 5
- 125000004450 alkenylene group Chemical group 0.000 claims description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 claims description 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 4
- 108010075324 emt protein-tyrosine kinase Proteins 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims description 2
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 2
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 claims description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 2
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 1
- 101710131689 Angiopoietin-1 receptor Proteins 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 abstract description 6
- 208000003950 B-cell lymphoma Diseases 0.000 abstract description 6
- 229910052740 iodine Inorganic materials 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 33
- 230000005764 inhibitory process Effects 0.000 description 23
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 13
- 238000000134 MTT assay Methods 0.000 description 11
- 231100000002 MTT assay Toxicity 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000036210 malignancy Effects 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 125000004404 heteroalkyl group Chemical group 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 210000002997 osteoclast Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102100027907 Cytoplasmic tyrosine-protein kinase BMX Human genes 0.000 description 5
- 101000935548 Homo sapiens Cytoplasmic tyrosine-protein kinase BMX Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- 0 C*CCC(C(Nc1c2)=O)=Nc1cc1c2nc(-c(cc2)cc3c2[n](*)c2c3cccc2)[n]1C Chemical compound C*CCC(C(Nc1c2)=O)=Nc1cc1c2nc(-c(cc2)cc3c2[n](*)c2c3cccc2)[n]1C 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010025832 RANK Ligand Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000013152 negative regulation of cell migration Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000004957 autophagosome Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical class OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000501754 Astronotus ocellatus Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100035634 B-cell linker protein Human genes 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZUMIOMVVVMZOPH-CMDGGOBGSA-N CC(C(Nc1c2)=O)=Nc1cc1c2nc(/C=C/c2ccccc2)[n]1C Chemical compound CC(C(Nc1c2)=O)=Nc1cc1c2nc(/C=C/c2ccccc2)[n]1C ZUMIOMVVVMZOPH-CMDGGOBGSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- UVSVTDVJQAJIFG-VURMDHGXSA-N LFM-A13 Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC(Br)=CC=C1Br UVSVTDVJQAJIFG-VURMDHGXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- BSSBAJKNZOHHCA-UHFFFAOYSA-N O=C(C(Cc1ccccc1)=Nc1c2)Nc1cc1c2[n](CCCN2CCCCC2)c(-c(cc2)ccc2-c2ccncc2)n1 Chemical compound O=C(C(Cc1ccccc1)=Nc1c2)Nc1cc1c2[n](CCCN2CCCCC2)c(-c(cc2)ccc2-c2ccncc2)n1 BSSBAJKNZOHHCA-UHFFFAOYSA-N 0.000 description 1
- LGXOQSPUPJMVEY-UHFFFAOYSA-N O=C(C(Cc1ccccc1)=Nc1c2)Nc1cc1c2[n](CCCN2CCCCC2)c(-c2ccc(-c3ccncc3)[s]2)n1 Chemical compound O=C(C(Cc1ccccc1)=Nc1c2)Nc1cc1c2[n](CCCN2CCCCC2)c(-c2ccc(-c3ccncc3)[s]2)n1 LGXOQSPUPJMVEY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- GRADOOOISCPIDG-UHFFFAOYSA-N buta-1,3-diyne Chemical group [C]#CC#C GRADOOOISCPIDG-UHFFFAOYSA-N 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- 102000002717 c-Mer Tyrosine Kinase Human genes 0.000 description 1
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000004978 cyclooctylene group Chemical group 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005062 perfluorophenyl group Chemical group FC1=C(C(=C(C(=C1F)F)F)F)* 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- Etk epidermal and endothelial tyrosine kinase
- Btk Bruton's tyrosine kinase
- Etk Overexpression of Etk is associated with the development of advanced prostate cancer and transgenic mice bearing this gene developed preneoplastic lesions of prostate cancer (Dai et al, 2006). Etk is also highly expressed in endothelial cells and involved in angiogenesis and metastasis (Zhang et al., 2003; Chang et al, 2007). There is also evidence that Etk plays a role in breast carcinogenesis, hepatocellular carcinoma, and nasopharyngeal cancer (Bagheri et al, 2001 ; Guo et al, 2006, 2007, 2008). Etk inhibitors thus would block growth of epithelial tumors and the processes of angiogenesis and metastasis.
- Btk another family member, is expressed at high levels in B cells and B cell malignancies. Btk is critical for the maturation and activation of B cells. Btk is important for the survival of many leukemia cells and plays an important role in immune responses.
- Btk tyrosine kinases in Tec family
- Itk and Tec are also implicated in carcinogenesis (Chang et al. , 2007).
- the present invention provides compounds of Formula I:
- Radical R 1 of Formula I can be H, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, C] -6 haloalkyl, OR la , C ]-6 alkyl-OR la , -NR la R lb , -C 1 -6 alkyl -NR 13 R 1 b , -C(O)R la , -C(O)OR la , -OC(O)OR 13 , -C(O)NR 13 R 1 b , -NR 13 C(O)R 1 b , -OC(O)NR 13 R 1 b , -NR 13 C(O)OR 1 b ,
- Radical L 1 of Formula I can be a bond, Ci -6 alkylene or Ci -6 heteroalkylene.
- Radical R 2 of Formula I can be C 1-6 alkyl, -NR 2a R 2b , C 3-9 heterocycloalkyl, aryl or heteroaryl, each optionally substituted with 1 to 4 R 5 substituents.
- Radical L 2 of Formula I can be a bond, Ci -6 alkylene, Ci -6 heteroalkylene or Ci -6 alkylene-C(O)-.
- Racial R 3 of Formula I can be -NR 6a R 6b , C 3-J0 cycloalkyl, C 3-9 heterocycloalkyl, aryl, aryl-oxy, heteroaryl or heteroaryl-oxy, each optionally substituted with 1 to 4 R 5 substituents.
- Radical L 3 of Formula I can be a bond, C 2-6 alkenylene and C 2-6 alkynylene, cycloalkylene, heterocycloalkylene, arylene or heteroarylene.
- Radical R 4 of Formula I can be H or C ]-6 alkyl.
- Each of radical R 5 of Formula I can separately be Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, C 1-6 haloalkyl, Ci -6 haloalkoxy, OR 53 , Ci -6 alkyl-OR 5a , aryl, heteroaryl, -NR 5a R 5b , Ci- ⁇ alkylaryl, -C 1-6 alkyl-heteroaryl, -C 1 -6 alkyl-NR 5a R 5b , -C(0)R 5a , -C(0)0R 5a , -OC(O)OR 53 , -C(O)NR 5a R 5b , -NR 5a C(O)R 5b , -OC(O)NR 5a R 5b , -NR 5a C(O)OR 5b ,
- Each of radicals R 6a and R 6b of Formula I can separately be H or Cj -6 alkyl, wherein the Ci -6 alkyl group can optionally be substituted with C 2-6 alkenyl, C 2-6 alkynyl, halogen, Ci- 6 haloalkyl, OR 5a , -NR 5a R 5b , -C(O)R 5a , -C(O)OR 5a , -OC(O)OR 53 , -C(O)NR 5a R 5b ,
- Radical X of Formula I can be -O- or -N(R 7 )-.
- Radical Y of Formula I can be C 1 -6 alkylene, Ci -6 heteroalkylene or heterocycloalkyl.
- Subscript n of Formula I can be 0 or 1.
- radicals R la , R I b , R 2a , R 2b , R 5a , R 5b and R 7 of Formula I can separately be H or Ci- 6 alkyl.
- radicals R la and R lb , R 2a and R 2b , R 5a and R 5b , or R 7 and Y are optionally combined with the atom to which each is attached to form a C 3-8 heterocycloalkyl which can optionally be substituted with Ci -6 alkyl.
- two R 5 groups are combined to form a C 3 - 8 heterocycloalkyl which can optionally be substituted with Ci -6 alkyl.
- the present invention provides a pharmaceutical composition of a compound of Formula I and a pharmaceutically acceptable excipient.
- the present invention provides a method of treating B-cell leukemia or B-cell lymphoma, prostate cancer, or osteoporosis, by administering to a subject in need thereof, a pharmaceutically acceptable amount of a compound of Formula I.
- the present invention provides a method for the inhibition of Btk, Etk, or Mertk by administering to a subject in need thereof, a pharmaceutically acceptable amount of a compound of Formula I.
- Figure 1 shows a scheme for the preparation of the compounds of the present invention.
- Figure 2 shows the viability of LnCaP cells following treatment of compounds at 10 ⁇ M was measured using an MTT assay.
- Figures 3A and 3B shows autophagy in CWR22Rvl-LC3 cells.
- Figure 3A shows autophagosomes as visualized by GFP-LC3 "puncta.”
- Figure 3B shows an immunoblot (CWR22Rvl) of endogenous LC3 isoforms.
- Figure 4 shows inhibition of cell migration of PC3 human prostate cancer cells by compounds of the present invention.
- Figure 5 shows inhibition of Btk kinase activity of compounds of the present invention.
- Figure 6 shows inhibition of Etk kinase activity of a compound of the present invention.
- Figure 7 shows percent growth of BCBLl, LnCap and RWPEl (immortalized human prostate cells) for compounds of the present invention at 20 ⁇ M. The data was obtained using the MTT assay described within.
- Figure 8 shows percent growth of BCBL 1 , LnCap and RWPE 1 (immortalized human prostate cells) for compounds of the present invention at 5 ⁇ M. The data was obtained using the MTT assay described within.
- Figure 9 shows percent growth of BCBLl, LnCap and RWPEl (immortalized human prostate cells) for compounds of the present invention at 1 ⁇ M. The data was obtained using the MTT assay described within.
- Figure 10 shows inhibition of Mertk kinase activity of compounds of the present invention.
- Figure 11 shows inhibition of Itk kinase activity of compounds of the present invention.
- CTA06 is a positive control compound. The data was obtained using the TLC kinase inhibition assay described within.
- Figure 12 shows growth inhibition of Jurkat, BCBLl, LnCap and RWPEl cells treated with compounds of the present invention. The data was obtained using the MTT assay described within. DETAILED DESCRIPTION OF THE INVENTION
- alkyl refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated.
- Ci-C 6 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc.
- Other alkyl groups include, but are not limited to heptyl, octyl, nonyl, decyl, etc.
- Alkyl can include any number of carbons, such as 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6 and 5-6.
- alkylene refers to an alkyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical.
- the two moieties linked to the alkylene can be linked to the same atom or different atoms of the alkylene.
- a straight chain alkylene can be the bivalent radical of -(CH 2 ) n; where n is 1, 2, 3, 4, 5 or 6.
- Alkylene groups include, but are not limited to, methylene, ethylene, propylene,
- heteroalkyl refers to an alkyl group, as defined above, having from 1 to 3 heteroatoms such as N, O and S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P.
- the heteroatoms can also be oxidized, such as, but not limited to, -S(O)- and -S(O) 2 -.
- heteroalkyl can include ethers, thioethers and alkyl-amines.
- the heteroalkyl group is typically monovalent, but can be divalent, such as when the heteroalkyl group links two moieties together, i.e., a
- heteroalkylene The two moieties linked to the heteroalkylene can be linked to the same atom or different atoms of the heteroalkylene.
- heteroalkylene refers to a heteroalkyl group, as defined above, linking at least two other groups.
- the two moieties linked to the heteroalkylene can be linked to the same atom or different atoms of the heteroalkylene.
- R', R 55 , R 5 ' 5 and R 5 ' 5 ' each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups.
- each of the R groups is independently selected as are each R', R", R'" and R"" groups when more than one of these groups is present.
- R' and R" When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
- -NR'R is meant to include, but not be limited to, 1 -pyrrolidinyl and 4-morpholinyl.
- alkenyl refers to either a straight chain or branched hydrocarbon of 2 to 6 carbon atoms, having at least one double bond.
- alkenyl groups include, but are not limited to, vinyl, propenyl, isopropenyl, 1 -butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1 ,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1 ,4-hexadienyl, 1,5-hexadienyl, 2,4- hexadienyl, or 1,3,5-hexatrienyl.
- Alkenyl groups can also have from 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6 and 5 to 6 carbons.
- the alkenyl groups is typically monovalent, but can be divalent, such as when the alkenyl group links two moieties together.
- alkenylene refers to an alkenyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical.
- the two moieties linked to the alkenylene can be linked to the same atom or different atoms of the alkenylene.
- Alkenylene groups include, but are not limited to, ethenylene, propenylene, isopropenylene, butenylene, isobutenylene, sec-butenylene, pentenylene and hexenylene.
- alkynyl refers to either a straight chain or branched hydrocarbon of 2 to 6 carbon atoms, having at least one triple bond.
- alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, isobutynyl, sec-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadiynyl, 1,4- pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1 ,4-hexadiynyl, 1,5- hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatri
- alkynylene refers to an alkynyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical.
- the two moieties linked to the alkynylene can be linked to the same atom or different atoms of the alkynylene.
- Alkynylene groups include, but are not limited to, ethynylene, propynylene, isopropynylene, butynylene, sec-butynylene, pentynylene and hexynylene.
- halogen refers to fluorine, chlorine, bromine and iodine.
- haloalkyl refers to alkyl group, as defined above, where some or all of the hydrogen atoms are substituted with halogen atoms.
- Halogen preferably represents chloro or fluoro, but may also be bromo or iodo.
- haloalkyl includes trifluoromethyl, fluoromethyl, 1, 2,3,4, 5-pentafluoro-phenyl, etc.
- perfluoro defines a compound or radical which has at least two available hydrogens substituted with fluorine.
- perfluorophenyl refers to 1,2,3,4,5- pentafluorophenyl
- perfluoromethane refers to 1,1,1 -trifluoromethyl
- perfluoromethoxy refers to 1,1,1-trifluoromethoxy
- alkoxy refers to alkyl group having an oxygen atom that either connects the alkoxy group to the point of attachment or is linked to two carbons of the alkoxy group.
- Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, etc.
- the alkoxy groups can be further substituted with a variety of substituents described within. For example, the alkoxy groups can be substituted with halogens to form a "halo-alkoxy" group.
- halo-alkoxy refers to an alkoxy group having at least one halogen.
- Halo-alkoxy is as defined for alkoxy where some or all of the hydrogen atoms are substituted with halogen atoms.
- the alkoxy groups can be substituted with 1, 2, 3, or more halogens.
- Halo-alkoxy includes, but is not limited to, trifluoromethoxy, 2,2,2,-trifluoroethoxy, perfluoroethoxy, etc.
- cycloalkyl refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated.
- Monocyclic rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl.
- Bicyclic and polycyclic rings include, for example, norbornane, decahydronaphthalene and adamantane.
- C 3-8 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and norbornane.
- cycloalkylene refers to a cycloalkyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the cycloalkylene can be linked to the same atom or different atoms of the cycloalkylene.
- Cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and cyclooctylene.
- the terms "heterocycle” or “heterocycloalkyl” refer to a ring system having from 3 ring members to about 20 ring members and from 1 to about 5 heteroatoms such as N, O and S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P. The heteroatoms can also be oxidized, such as, but not limited to, -S(O)- and -S(O) 2 -.
- heterocycle includes, but is not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, morpholino, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, piperidinyl, indolinyl, quinuclidinyl and 1 ,4-dioxa-8- aza-spiro[4.5]dec-8-yl.
- heterocycloalkylene refers to a heterocycloalkyl group, as defined above, linking at least two other groups. The two moieties linked to the
- heterocycloalkylene can be linked to the same atom or different atoms of the
- aryl refers to a monocyclic or fused bicyclic, tricyclic or greater, aromatic ring assembly containing 6 to 16 ring carbon atoms.
- aryl may be phenyl, benzyl or naphthyl, preferably phenyl.
- Arylene means a divalent radical derived from an aryl group.
- Aryl groups can be mono-, di- or tri-substituted by one, two or three radicals selected from alkyl, alkoxy, aryl, hydroxy, halogen, cyano, amino, amino-alkyl, trifluoromethyl, alkylenedioxy and oxy-C 2 -C 3 -alkylene; all of which are optionally further substituted, for instance as hereinbefore defined; or 1- or 2-naphthyl; or 1- or 2- phenanthrenyl.
- Alkylenedioxy is a divalent substitute attached to two adjacent carbon atoms of phenyl, e.g. methylenedioxy or ethylenedioxy.
- Oxy-C 2 -C 3 -alkylene is also a divalent substituent attached to two adjacent carbon atoms of phenyl, e.g. oxyethylene or
- oxypropylene An example for oxy- C 2 -C 3 -alkylene-phenyl is 2,3-dihydrobenzofuran-5-yl.
- Preferred as aryl is naphthyl, phenyl or phenyl mono- or disubstituted by alkoxy, phenyl, halogen, alkyl or trifluoromethyl, especially phenyl or phenyl-mono- or disubstituted by alkoxy, halogen or trifluoromethyl, and in particular phenyl.
- substituted phenyl groups as R are, e.g. 4-chlorophen-l-yl, 3,4- dichlorophen- 1 -yl, 4-methoxyphen- 1 -yl, 4-methylphen- 1 -yl, 4-aminomethylphen- 1 -yl, A- methoxyethylaminomethylphen- 1 -yl, 4-hydroxyethylaminomethylphen- 1 -yl, 4-hydroxyethyl- (methyl)-aminomethylphen-l-yl, 3-aminomethylphen-l-yl, 4-N-acetylaminomethylphen-l- yl, 4-aminophen-l-yl, 3-aminophen-l-yl, 2-aminophen-l-yl, 4-phenyl-phen-l-yl, A- (imidazol-l-yl)-phen-yl, 4-(imidazol-l-ylmethyl)-phen-l-yl
- aryl-oxy refers to an aryl group, as defined above, where the aryl group is linked through an oxygen atom.
- Aryl-oxy groups include, but are not limited to, phenyl-oxy.
- arylene refers to an aryl group, as defined above, linking at least two other groups. The two moieties linked to the arylene are linked to different atoms of the arylene.
- Arylene groups include, but are not limited to, phenyl ene.
- arylene-oxy refers to an arylene group, as defined above, where one of the moieties linked to the arylene is linked through an oxygen atom.
- Arylene- oxy groups include, but are not limited to, phenylene-oxy.
- heteroaryl refers to a monocyclic or fused bicyclic or tricyclic aromatic ring assembly containing 5 to 16 ring atoms, where from 1 to 4 of the ring atoms are a heteroatom each N, O or S.
- heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl, furanyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any other radicals substituted, especially mono- or di-substituted, by e.g. alkyl, nitro or halogen.
- Pyridyl represents 2-, 3- or 4-pyridyl, advantageously 2- or 3- pyridyl.
- Thienyl represents 2- or 3-thienyl.
- Quinolinyl represents preferably 2-, 3- or A- quinolinyl.
- Isoquinolinyl represents preferably 1-, 3- or 4-isoquinolinyl.
- Benzopyranyl, benzothiopyranyl represents preferably 3 -benzopyranyl or 3-benzothiopyranyl, respectively.
- Thiazolyl represents preferably 2- or 4-thiazolyl, and most preferred, 4-thiazolyl.
- Triazolyl is preferably 1-, 2- or 5-(l,2,4-triazolyl).
- Tetrazolyl is preferably 5-tetrazolyl.
- heteroaryl is pyridyl, indolyl, quinolinyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, furanyl, benzothiazolyl, benzofuranyl, isoquinolinyl, benzothienyl, oxazolyl, indazolyl, or any of the radicals substituted, especially mono- or di-substituted.
- heteroaryl-oxy refers to a heteroaryl group, as defined above, where the heteroaryl group is linked through an oxygen atom.
- Heteroaryl -oxy groups include, but are not limited to, pyridyl-oxy.
- heteroarylene refers to an heteroaryl group, as defined above, linking at least two other groups. The two moieties linked to the heteroarylene are linked to different atoms of the heteroarylene.
- alkyl-aryl refers to a radical having an alkyl component and an aryl component, where the alkyl component links the aryl component to the point of attachment.
- the alkyl component is as defined above, except that the alkyl component is at least divalent in order to link to the aryl component to the point of attachment. In some instances, the alkyl component can be absent.
- the aryl component is as defined above. Examples of alkyl-aryl groups include, but are not limited to, benzyl.
- alkyl-heteroaryl refers to a radical having an alkyl component and an heteroaryl component, where the alkyl component links the heteroaryl component to the point of attachment.
- the alkyl component is as defined above, except that the alkyl component is at least divalent in order to link to the heteroaryl component to the point of attachment. In some instances, the alkyl component can be absent.
- the heteroaryl component is as defined above.
- salt refers to acid or base salts of the compounds used in the methods of the present invention.
- pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.
- salts of the acidic compounds of the present invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and
- prodrug refers to covalently bonded carriers which are capable of releasing the active agent of the methods of the present invention, when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs in vivo.
- Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups by routine manipulation or in vivo.
- Prodrugs of the active agents of the present invention include active agents wherein a hydroxy, amidino, guanidino, amino, carboxylic or a similar group is modified.
- the term "pharmaceutically acceptable excipient” refers to a substance that aids the administration of an active agent to and absorption by a subject.
- Pharmaceutical excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors.
- binders include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors.
- the terms “treat”, “treating” and “treatment” refers to any indicia of success in the treatment or amelioration of an injury, pathology, condition, or symptom (e.g., pain), including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the symptom, injury, pathology or condition more tolerable to the patient; decreasing the frequency or duration of the symptom or condition; or, in some situations, preventing the onset of the symptom or condition.
- the treatment or amelioration of symptoms can be based on any objective or subjective parameter; including, e.g., the result of a physical examination.
- Subject refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human.
- the compounds of the present invention are those of
- Radical R of Formula I can be H, d -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, Ci -6 haloalkyl, OR la , C -6 alkyl-OR la , -NR la R lb , -C,_ 6 alkyl-NR la R Ib , -C(O)R la , -C(O)OR la , -OC(O)OR 13 , -C(O)NR la R lb , -NR la C(O)R lb , -OC(O)NR la R lb , -NR la C(O)OR lb , -NR la C(O)OR lb ,
- Radical L 1 of Formula I can be a bond, Ci -6 alkylene or Ci -6 heteroalkylene.
- Radical R 2 of Formula I can be C 1 -6 alkyl, -NR 2a R 2b , C 3-9 heterocycloalkyl, aryl or heteroaryl, each optionally substituted with 1 to 4 R 5 substituents.
- Radical L 2 of Formula I can be a bond, Ci -6 alkylene, Cj -6 heteroalkylene or Ci -6 alkylene-C(O)-.
- Racial R 3 of Formula I can be -NR 6a R 6b , C 3-I0 cycloalkyl, C 3-9 heterocycloalkyl, aryl, aryl-oxy, heteroaryl or heteroaryl-oxy, each optionally substituted with 1 to 4 R 5 substituents.
- Radical L 3 of Formula I can be a bond, C 2-6 alkenylene and C 2-6 alkynylene, cycloalkylene, heterocycloalkylene, arylene or heteroaryl ene.
- Radical R 4 of Formula I can be H or C 1-6 alkyl.
- Each of radical R 5 of Formula I can separately be Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, Q -6 haloalkyl, C 1-6 haloalkoxy, OR 5a , C 1-6 alkyl-OR 5a , aryl, heteroaryl, -NR 5a R 5b , C 1-6 alkylaryl, -C 1-6 alkyl-heteroaryl, -C 1-6 alkyl-NR 5a R 5b , -C(O)R 5a , -C(O)OR 5a ,
- -NR 5a C(O)NR 5a R 5b , -CN, -NO 2 , -N 3 , ( 0), -SR 5a , -S(O)R 5a , -S(O) 2 R 5a , -NR 5a S(O) 2 R 5b , -NR 5a S(O) 2 aryl, -S(O) 2 NR 5a R 5b , -NR 5a S(O) 2 NR 5a R 5b or heteroaryl-oxy.
- Radical X of Formula I can be -O- or -N(R 7 )-.
- Radical Y of Formula I can be C 1-6 alkylene, C 1-6 heteroalkylene or heterocycloalkyl.
- Subscript n of Formula I can be 0 or 1.
- Each of radicals R la , R lb , R 2a , R 2b , R 5a , R 5b and R 7 of Formula I can separately be H or C 1-6 alkyl.
- radicals R la and R lb , R 2a and R 2b , R 5a and R 5b , or R 7 and Y are optionally combined with the atom to which each is attached to form a C 3-8 heterocycloalkyl which can optionally be substituted with C 1-6 alkyl.
- two R 5 groups are combined to form a C 3 - 8 heterocycloalkyl which can optionally be substituted with C 1-6 alkyl.
- Radical R 1 of Formula I can be C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, C 1-6 haloalkyl, OR la , C 1-6 alkyl-OR la , -NR l a R lb , -C 1-6 alkyl-NR l a R Ib , -C(O)R I a , -C(O)OR 13 , -OC(O)OR' 3 , -C(O)NR l3 R lb , -NR l3 C(0)R lb , -OC(O)NR l a R lb , -NR la C(O)OR i b , -NR !a C(0)NR la R lb , -CN, -NO 2 , -N 3 , -SR la , -S(O)R 13 , -S(O) 2 R 13
- Radical L 1 of Formula I can be a bond, C 1 -6 alkylene or C 1-6 heteroalkylene.
- Radical R of Formula I can be C 1-6 alkyl, -NR 2a R 2b , C 3-9 heterocycloalkyl, aryl or heteroaryl, each optionally substituted with 1 to 4 R 5 substituents.
- Radical L of Formula I can be a bond, C 1-6 alkylene, Ci -6 heteroalkylene or Q -6 alkylene-C(O)-.
- Racial R 3 of Formula I can be -NR 6a R 6b , C 3-I0 cycloalkyl, C 3-9 heterocycloalkyl, aryl, aryl-oxy, heteroaryl or heteroaryl-oxy, each optionally substituted with 1 to 4 R 5 substituents.
- Radical L 3 of Formula I can be a bond, C 2-6 alkenylene and C 2-6 alkynylene, cycloalkylene, heterocycloalkylene, arylene or heteroarylene.
- Radical R 4 of Formula I can be H or Ci -6 alkyl.
- Radical Y of Formula I can be Cj -6 alkylene, Ci -6 heteroalkylene or heterocycloalkyl.
- Subscript n of Formula I can be O or 1.
- Each of radicals R l a , R lb , R 2a , R 2b , R 5a , R 5b and R 7 of Formula I can separately be H or Ci -6 alkyl.
- radicals R l a and R Ib , R 2a and R 2b , R 5a and R 5b , or R 7 and Y are optionally combined with the atom to which each is attached to form a C 3-8 heterocycloalkyl.
- radical R 1 of Formula I can be Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, Ci -6 haloalkyl, OR l a , C 1-6 alkyl-OR la , -NR la R lb , -C 1-6 alkyl-NR l a R lb , -C(O)R la , -C(O)OR !
- -OC(O)OR 13 -C(0)NR la R lb , -NR la C(O)R lb , -OC(O)NR 13 R 1 b , -NR la C(0)0R lb , -NR la C(O)NR la R lb , -CN, -NO 2 , -N 3 , -SR la , -S(O)R la , -S(O) 2 R la ,
- the compounds of the present are those of Formula Ia:
- radical R 1 of Formula Ia can be Ci -6 alkyl, OR la , -NR !a R ib , -C(O)R la , -C(O)OR l a , -OC(O)OR 13 , -C(0)NR la R lb , -NR la C(O)R lb , -0C(0)NR la R lb , -NR la C(O)OR Ib , -NR la C(0)NR la R lb , -SR la , -S(O)R 1 a , -S(O) 2 R 13 , -NR la S(0) 2 R !b ,
- Radical L 1 of Formula Ia can be Cj -6 alkylene.
- Radical R 2 of Formula Ia can be C 3-9 heterocycloalkyl.
- Radical L 2 of Formula Ia can be Ci -6 alkylene.
- Radical R 3 of Formula Ia can be aryl or heteroaryl.
- Radical L 3 of Formula Ia can be a bond or C 2-6 alkenylene.
- L 1 is a bond or Ci -6 alkylene.
- R 1 is aryl. In some other embodiments, R 1 is phenyl. In still other embodiments, R 5 can be H, halogen, or Ci -6 haloalkyl. In yet other embodiments, R 5 is F or Cl. In another embodiment, L 1 is a bond or Ci -6 alkylene, and R 1 is aryl.
- L 2 can be Ci -6 alkylene.
- R 2 can be heterocycloalkyl.
- R 2 can be a nitrogen containing heterocycloalkyl.
- radical R 2 can be aziridine, azetidane, 1,3-diazazitidine, pyrolidine, pyrolidin-2-one, piperidine, 1,2-piperazine, 1,3-piperazine, 1 ,4-piperazine, or azocane.
- R 2 can be a C 5-6 heterocycloalkyl containing one nitrogen heteroatom.
- L 2 is Ci -6 alkylene and R 2 is a heterocycloalkyl.
- L 3 is a bond, arylene or heteroarylene.
- L 3 is a bond. In some other embodiments, L 3 is arylene, such as phenylene. In yet other embodiments, L 3 is heteroarylene, such as thiophene.
- R 3 is heteroaryl.
- radical R 3 can be phenyl, pyrrole, pyrazole, imidzaole, pyridine, pyrimidine, pyrazine, pyridazine, 1 ,2,4- triazine, 1,3,5-triazine, pyrrolizine, indole, quinoline, isoquinoline, benzimidazole, indazole, quinolizine, cinnoline, quinazoline, phthalazine, naphthyridine, carboline, or carbazole.
- L 3 is aryl or heteroaryl
- R 3 is heteroaryl.
- R 1 , L 3 and R 3 is aryl, arylene, heteroaryl or heteroarylene. In some embodiments, at least one of R 1 and R 3 is aryl or heteroaryl. In other embodiments, at least one of L 3 and R 3 is heteroaryl or heteroarylene.
- R 1 is phenyl, optionally substituted with halogen, L 1 is a bond or Ci -6 alkylene, R 2 is piperidine, L 2 is Ci -6 alkylene, R 3 is a heteroaryl, L 3 is selected from the group consisting of a bond, phenylene or thiophene, and R 4 is hydrogen.
- radical R 1 of Formula Ia can be C ]-6 alkyl, -C(O)OR l a or phenyl.
- Radical L 1 of Formula Ia can be Ci -6 alkylene.
- Radical R 2 of Formula Ia can be pyrolidine or pyrolidin-2-one.
- Radical L 2 of Formula Ia can be Ci -6 alkylene.
- Radical R 5a of Formula Ia can be Cj -6 alkyl.
- Radical R 3 of Formula Ia can be phenyl or carbazole. Radical L 3 of Formula Ia can be a bond or C 2-6 alkenylene.
- R is Ci -6 alkyl
- the compounds of Formula I can be any organic compound having the same or similarity. [0094] in some embodiments, the compounds of Formula I can be any organic compound having the same or identical to the compounds of Formula I.
- the compound can have the formula:
- L 1 is a bond or Ci -6 alkylene, and R 5 is H or halogen. In yet other embodiments, L ! is a bond. In still yet other embodiments, L 1 is Ci -6 alkylene. In some other embodiments, R 5 is H. In still other embodiments, R 5 is halogen. In yet other embodiments, R 5 is F or Cl. In some other embodiments, L 2 is Ci -6 alkylene and R 2 is a C 5-6 heterocycloalkyl containing 1 N heteroatom. In still other embodiments, L is a bond, arylene or heteroarylene, and R 3 is heteroarylene. In other embodiments, L 3 is a bond. In some other embodiments, L 3 is phenylene. In still other embodiments, L is thiophene. In another embodiment, R 3 is pyridyl. In some embodiments, R 3 is 4-pyridyl. In some embodiments, the compounds can have the formula:
- the compound can have the formula:
- the compounds of Formula I can be any organic compound having the same or similarity. [0096] in some other embodiments, the compounds of Formula I can be any organic compound having the same or similarity.
- the compounds of Formula I can be [0099] In still other embodiments, the compound can be:
- the compound of the present invention can be CTAOOl, CTA020, CTA033, CTA036, CTA041, CTA042, CTA045, CTA047, CTA048, CTA051, CTA056, CTA065, CTA067, CTA 109, or CTAl 21.
- the compound of the present invention can be CTA004, CTA008, CTAOl 3, CTA014, CTAOl 7, CTA038, CTA040, or CTA062.
- the compound of the present invention can be CTAOOl, CTA004, CTA008, CTA013, CTA014, CTA017, CTA020, CTA033, CTA036, CTA038, CTA040, CTA041, CTA042, CTA045, CTA047, CTA048, CTA051, CTA056, CTA065, CTA067, CTA109, or CTA121.
- the compound can be CTAOOl, CTA020, CTA033, CTA036, CTA041, CTA042, CTA045, CTA047, CTA048, CTA051, CTA056, CTA062, CTA065, CTA067, CTA109, or CTA121.
- the compound is CTA056. In still yet other embodiments, the compound can be CTA056, CTA092, CTA093, CTA095, CTA097 or CTA099. In another embodiment, the compound can be CTA129, CTA151, CTA163 or CTA164. In some embodiments, the compound can be CTAl 51. In another embodiment, the compound can be CTA056 or CTA151.
- salts of the acidic compounds of the present invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and
- acid addition salts such as of mineral acids, organic carboxylic and organic sulfonic acids, e.g., hydrochloric acid, methanesulfonic acid, maleic acid
- a basic group such as pyridyl
- the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
- Prodrug and metabolite forms of the compounds of the present invention are also included in the present invention.
- the compounds of the present invention can be formulated in a variety of different manners known to one of skill in the art.
- Pharmaceutically acceptable excipients are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there are a wide variety of suitable formulations of pharmaceutical compositions of the present invention (see, e.g., Remington 's Pharmaceutical Sciences, 20 th ed., 2003, supra).
- the compounds of the present invention can be prepared and administered in a wide variety of oral, injectible and topical dosage forms.
- the compounds of the present invention can also be prepared and administered in parenteral dosage forms.
- the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
- the compounds described herein can be administered by inhalation, for example, intranasally.
- the compounds of the present invention can be administered transdermally or topically, e.g., in a liquid or gel form or as a patch.
- Formulations suitable for administration can consist of (a) liquid solutions, such as an effective amount of a compound of the present invention suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets, depots or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; (d) suitable emulsions; and (e) patches.
- liquid solutions such as an effective amount of a compound of the present invention suspended in diluents, such as water, saline or PEG 400
- capsules, sachets, depots or tablets each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin
- suspensions in an appropriate liquid such as suitable emulsions; and (e) patches.
- pharmaceutical forms can include a pharmaceutically acceptable excipient, such as one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.
- a pharmaceutically acceptable excipient such as one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives,
- Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
- a flavor e.g., sucrose
- an inert base such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
- the pharmaceutical preparation is preferably in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- the composition can, if desired, also contain other compatible therapeutic agents.
- Preferred pharmaceutical preparations can deliver the compounds of the invention in a sustained release formulation.
- the pharmaceutical preparations are typically delivered to a mammal, including humans and non-human mammals.
- Non-human mammals treated using the present methods include domesticated animals ⁇ i.e., canine, feline, murine, rodentia, and lagomorpha) and agricultural animals (bovine, equine, ovine, porcine).
- the compounds of the present invention can be administered as frequently as necessary, including hourly, daily, weekly or monthly.
- the compounds utilized in the pharmaceutical method of the invention are administered at the initial dosage of about 0.0001 mg/kg to about 1000 mg/kg daily.
- a daily dose range of about 0.01 mg/kg to about 500 mg/kg, or about 0.1 mg/kg to about 200 mg/kg, or about 1 mg/kg to about 100 mg/kg, or about 10 mg/kg to about 50 mg/kg, can be used.
- the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. For example, dosages can be empirically determined considering the type and stage of disease diagnosed in a particular patient.
- the dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time.
- the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular compound in a particular patient. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired. Doses can be given daily, or on alternate days, as determined by the treating physician.
- Doses can also be given on a regular or continuous basis over longer periods of time (weeks, months or years), such as through the use of a subdermal capsule, sachet or depot, or via a patch.
- the pharmaceutical compositions can be administered to the patient in a variety of ways, including topically, parenterally, intravenously, intradermally, intramuscularly, colonically, rectally or intraperitoneally.
- the pharmaceutical compositions are administered parenterally, topically, intravenously, intramuscularly or orally.
- the pharmaceutically effective amount of a composition required as a dose will depend on the route of administration, the type of disease being treated, and the physical characteristics of the patient.
- the dose can be tailored to achieve a desired effect, but will depend on such factors as body surface area, weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.
- the present invention provides a pharmaceutical composition of a compound of Formula I and a pharmaceutically acceptable excipient.
- the compounds of the present invention can be used to treat a variety of conditions.
- the compounds can be used to treat B-cell and T-cell malignancies, such as leukemia and lymphoma, cancer, such as prostate cancer, as well as osteoporosis.
- B-cell/T-cell malignancies such as leukemia and lymphoma
- cancer such as prostate cancer
- osteoporosis such as osteoporosis
- the compounds of the present invention are useful for the treatment of a variety of B-cell and T-cell malignancies.
- B-cells (Bone-cells in mammals) and T-cells are
- B-cells primarily make antibodies (known as plasma B-cells) in response to an antigen, thereby tagging the antigen for destruction.
- Plasma B-cells are activated in response to an antigen and are formed from memory B-cells.
- Memory B-cells are long lived B-cells that have been exposed to the antigen previously (exposure of a na ⁇ ve B-cell to the antigen), and thus "remember" the antigen and are able to mount a quicker response via the plasma B-cells than would otherwise be possible.
- B-cell and T-cell malignancies include, but are not limited to, autoimmune disorders, leukemias such as B-cell acute lymphocytic leukemia and B-cell chronic lymphocytic leukemia, lymphomas such as non-Hodgkin's lymphomas and B-cell lymphoma, or multiple myeloma. Other B-cell and T-cell malignancies can be treated by the compounds of the present invention. [0119] Given the important role of Btk in B-cell malignancies, the activities of these agents to inhibit Btk was used to identify compounds for the treatment of B-cell malignancies. In addition, the effect of these agents on treatment of B-cell malignancies was also identified using BCBLl cells (human lymphoma cells) and MTT growth inhibition assay.
- BCBLl cells human lymphoma cells
- the present invention provides a method of treating leukemia or lymphoma, by administering to a subject in need thereof, a pharmaceutically acceptable amount of a compound of the present invention, thereby treating the leukemia or lymphoma.
- the leukemia or lymphoma can be treated by inhibiting Itk. In other embodiments, the leukemia or lymphoma can be treated by inhibiting Btk.
- the present invention provides a method of treating B-cell leukemia or B-cell lymphoma, by administering to a subject in need thereof, a
- the compounds of the present invention are useful for the treatment of cancer, such as breast cancer, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, non- small cell lung cancer, brain cancer, cancer of the larynx, gall bladder, pancreas, rectum, parathyroid, thyroid, adrenal, neural tissue, head and neck, colon, stomach, bronchi, and kidney cancer, basal cell carcinoma, squamous cell carcinoma of both ulcerating and papillary type, metastatic skin carcinoma, osteo sarcoma, Ewing's sarcoma, veticulum cell sarcoma, myeloma, giant cell tumor, small-cell lung tumor, gallstones, islet cell tumor, primary brain tumor, acute and chronic lymphocytic and granulocytic tumors, hairy-cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuromas, intestinal ganglioneuromas, hyperplastic corneal nerve tumor, marfa
- cancer
- the cancer is prostate cancer.
- Compounds useful for the treatment of cancer can be identified by any number of methods known to one of skill in the art. For example, LnCaP cells can be seeded at 5,000 cells/well in 96-well plate overnight and treated with the compounds of the present invention. The cell viability can then be measured using any means known in the art, such as using an MTT assay. Using the assay described herein, compounds of Formula I were identified as active for the treatment of prostate cancer, see Table 3. Any prostate cancer cell line can be used to test for the efficacy of a compound of the present invention for the treatment of prostate cancer, for example, LnCaP, PC3, DU145 and CWR22Rvl . [0125] In some embodiments, the present invention provides a method of treating prostate cancer, by administering to a subject in need thereof, a pharmaceutically acceptable amount of a compound of Formula I, thereby treating the prostate cancer.
- Tyrosine Kinases of the Tec Family are useful for the inhibition of tyrosine kinases.
- Tyrosine kinases that can be inhibited by the compounds of the present invention include, but are not limited to, the Tec family and the Axl-Sky-Mer family of tyrosine kinases.
- Tyrosine kinases of the Tec family are involved in the regulation of immune functions, including T-cell signaling and activation.
- Tyrosine kinases of the Tec family include epithelial and endothelial tyrosine kinases (Etk), Bruton's tyrosine kinase (Btk), IL2- inducible T-cell kinase (Itk), among others.
- Tyrosine kinases of the Axl-Sky-Mer family are involved in leukemia, gastric cancer, prostate cancer, as well as immune diseases.
- Tyrosine kinases of the Axl-Sky-Mer family include the c-mer protooncogene tyrosine kinase, or Mer tyrosine kinase (Mertk).
- Compounds useful for the inhibition of tyrosine kinase activity can be identified by any number of methods known to one of skill in the art. For example, compounds can be incubated with Btk and a substrate, such as YIYGSFK, in a kinase reaction using 33 P-ATP. The products of the reaction can be analyzed by any means known to one of skill in the art. For example, the product can be analyzed on a TLC (Thin Layer Chromatography) plate to determine if the compound inhibits Btk. The same assay is useful for the identification of compounds that inhibit other tyrosine kinases, such as Etk, Itk and Mertk. When Mertk is the target, the substrate can be TSFYGRH.
- the present invention provides a method for the inhibition of Bruton's tyrosine kinase (Btk) by administering to a subject in need thereof, a
- the present invention provides a method for the inhibition of epithelial and endothelial tyrosine kinases (Etk) by administering to a subject in need thereof, a pharmaceutically acceptable amount of a compound of Formula I 5 thereby inhibiting Etk.
- Etk epithelial and endothelial tyrosine kinases
- the present invention provides a method for the inhibition of Mer tyrosine kinase (Mertk) by administering to a subject in need thereof, a pharmaceutically acceptable amount of a compound of Formula I, thereby inhibiting Mertk.
- the present invention provides a method for the inhibition of IL2-inducible T-cell kinase (Itk) by administering to a subject in need thereof, a
- the present invention provides a method of inhibiting a tyrosine kinase including epithelial and endothelial tyrosine kinases (Etk), Bruton's tyrosine kinase (Btk), Mer tyrosine kinase (Mertk) or IL2-inducible T-cell kinase (Itk), the method comprising administering to a subject in need thereof, a pharmaceutically acceptable amount of a compound of the present invention, thereby inhibiting the tyrosine kinase.
- Etk epithelial and endothelial tyrosine kinases
- Btk Bruton's tyrosine kinase
- Mertyrosine kinase Mer tyrosine kinase
- Itk IL2-inducible T-cell kinase
- the compounds of the present invention are useful for the treatment of osteoporosis.
- Bruton's tyrosine kinase (Btk) and tyrosine kinase (Tec), tyrosine kinases essential for B cell development, have been shown to regulate osteoclast differentiation by linking two essential pathways for osteoclast differentiation: RANKL and ITAM.
- RANK and ITAM signaling both signal through formation of a Btk(Tec)/BLNK(SLP-76)-containing complex and PLC- mediated activation of calcium signal (J Immunol 2009, 182(l):329-339).
- Mice with tyrosine kinases Btk and Tec knockdown developed severe osteoporosis that was associated with a defect in bone resorption.
- Compounds of the present invention useful as small molecule inhibitors of Btk can be used to decrease osteoclast activation and prevent bone loss.
- Such compounds can be identified using bone marrow cells (BMMs) from 2-month-old C57BL mice.
- the BMMs can be cultured with the compound (at 0, 10 "10 , 10 "8 , 10 "6 M) supplemented with 20ng/ml mCSF and 100ng/ml RANKL for 7-10 days.
- TRAP+ cell formation, representing mature osteoclasts, can be monitored. Dentine resorption pit area can also be monitored.
- the present invention provides a method of treating osteoporosis, by administering to a subject in need thereof, a pharmaceutically acceptable amount of a compound of Formula I, thereby treating osteoporosis.
- CWR22Rvl and LNCaP cells stably transfected with GFP-LC3 were examined under fluorescence microscopy, 24 hours after treatment with either CTA003 or 6RF3 at 10 ⁇ M concentration.
- the autophagic process started as early as 4 hours post-treatment and lasts for at least 36 hours.
- Cells treated with different level of CTA003 were further examined for the conversion of endogenous LC3-I to LC3-II forms.
- Figure 3 A shows autophagosomes as visualized by GFP-LC3 "puncta.”
- Figure 3B shows an immunoblot (CWR22Rvl) of endogenous LC3 isoforms.
- PC3 cells were grown to the indicated confluence (0 h) and treated with the corresponding agents (5 ⁇ M). Cell migration was visualized using "wound-healing" assay (0 h and 24 h). (See Figure 4.)
- Inhibition of Btk kinase activity was determined by incubating purified Btk (50 nM) and the corresponding compounds with the substrate (YIYGSFK) in a kinase reaction.
- LFM-A 13 is a known Btk inhibitor and was used as a control in these experiments (Uckun, 2008).
- Figure 5 shows the inhibition of Btk using the compounds of the present invention, as well as the concentration-dependent inhibition of Btk by CTA041, CTA008, and CTA013 compared with LFM-A13.
- BMMs bone marrow cells
- CTA013 at 0, 10 ⁇ 10 , 10 "8 , 10 "6 M
- 20ng/ml mCSF and lOOng/ml RANKL for 7-10 days.
- TRAP+ cells formation representing mature osteoclasts, were found to decrease by 12% , 30-40% and more than 90%, respectively, in 10 "10 , 10 "8 , 10 "6 M.
- Dentine resorption pit area was about 40% lower in the 10 "10 M concentration and was not detectable in 10 ⁇ 8 and 10 "6 M concentrations.
- CTAO 13 was found to exhibit similar effects on gene expression that associate with osteoclastogenesis.
- OSCAR receptor for Fc ⁇
- Trem2 receptor for Dap 12
- TRAF6 a key signaling adaptor for RANK
- Trap5b osteoclast maturation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention porte sur des composés de Formule I ainsi que sur des compositions pharmaceutiques comprenant des composés de Formule I. La présente invention porte également sur des procédés de traitement d'une leucémie et d'un lymphome à cellules B, d'un cancer de la prostate et de l'ostéoporose. La présente invention porte également sur des procédés d'inhibition de Btk, Etk, Itk et Mer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23092509P | 2009-08-03 | 2009-08-03 | |
US61/230,925 | 2009-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011017219A1 true WO2011017219A1 (fr) | 2011-02-10 |
Family
ID=43544606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/043927 WO2011017219A1 (fr) | 2009-08-03 | 2010-07-30 | Imidazoquinoxalinones et traitement anti-tumoral |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011017219A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013153539A1 (fr) * | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Composés tricycliques à titre d'inhibiteurs de kinases tec |
WO2014065440A1 (fr) * | 2012-10-26 | 2014-05-01 | Canon Kabushiki Kaisha | Médicament inhibiteur de cellules cancéreuses et sonde de détection de cellules souches cancéreuses |
CN103804307A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
EP2726077A4 (fr) * | 2011-06-28 | 2014-12-10 | Pharmacyclics Inc | Procédés et compositions visant à inhiber la résorption osseuse |
WO2017040617A1 (fr) | 2015-08-31 | 2017-03-09 | Pharmacyclics Llc | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple |
WO2018085731A2 (fr) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Polythérapie de type thérapie cellulaire t et inhibiteur de btk |
WO2019213184A1 (fr) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Polythérapie d'une thérapie par lymphocytes t à récepteur antigénique chimérique (car) et d'un inhibiteur de btk |
EP4115886A1 (fr) | 2013-10-25 | 2023-01-11 | Pharmacyclics LLC | Procédés de traitement et de prévention de la maladie du greffon contre l'hôte |
WO2023220655A1 (fr) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040157852A1 (en) * | 1997-08-05 | 2004-08-12 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
US20080125418A1 (en) * | 2001-10-26 | 2008-05-29 | Aventis Pharma S.A. | Benzimidazole derivatives and their use as kdr kinase protein inhibitors |
-
2010
- 2010-07-30 WO PCT/US2010/043927 patent/WO2011017219A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040157852A1 (en) * | 1997-08-05 | 2004-08-12 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
US20080125418A1 (en) * | 2001-10-26 | 2008-05-29 | Aventis Pharma S.A. | Benzimidazole derivatives and their use as kdr kinase protein inhibitors |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2726077A4 (fr) * | 2011-06-28 | 2014-12-10 | Pharmacyclics Inc | Procédés et compositions visant à inhiber la résorption osseuse |
WO2013153539A1 (fr) * | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Composés tricycliques à titre d'inhibiteurs de kinases tec |
WO2014065440A1 (fr) * | 2012-10-26 | 2014-05-01 | Canon Kabushiki Kaisha | Médicament inhibiteur de cellules cancéreuses et sonde de détection de cellules souches cancéreuses |
US10220024B2 (en) | 2012-10-26 | 2019-03-05 | Canon Kabushiki Kaisha | Method of inhibiting cancer cell, method for detecting cancer cell, and system for detecting cancer cell |
CN103804307A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
EP4115886A1 (fr) | 2013-10-25 | 2023-01-11 | Pharmacyclics LLC | Procédés de traitement et de prévention de la maladie du greffon contre l'hôte |
WO2017040617A1 (fr) | 2015-08-31 | 2017-03-09 | Pharmacyclics Llc | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple |
WO2018085731A2 (fr) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Polythérapie de type thérapie cellulaire t et inhibiteur de btk |
WO2019213184A1 (fr) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Polythérapie d'une thérapie par lymphocytes t à récepteur antigénique chimérique (car) et d'un inhibiteur de btk |
WO2023220655A1 (fr) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011017219A1 (fr) | Imidazoquinoxalinones et traitement anti-tumoral | |
CN111646995B (zh) | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 | |
RU2762893C2 (ru) | Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли | |
US9464093B2 (en) | Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer | |
EP3843741A1 (fr) | Inhibiteurs de kinase ire1 et leurs utilisations | |
CN117447470A (zh) | 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用 | |
EP2519518B1 (fr) | Dichloroacétate d'imatinib et agent anticancéreux le comprenant | |
US10087149B2 (en) | Selective histone deacetylase 8 inhibitors | |
EP3279201B1 (fr) | Inhibiteur de cdk, cristal eutectique d'inhibiteur de mek, et leur procédé de préparation | |
JP2021527692A (ja) | Oat3の阻害剤を用いた神経変性に関連する状態の処置方法 | |
KR20230106610A (ko) | 치료제로서의 석시네이트 및 이의 결정 형태 | |
CN113811302B (zh) | 激酶抑制剂的用途 | |
EP4009973B1 (fr) | Compositions pharmaceutiques de (6as)-6-méthyl -5,6,6a,7-tétrahydro-4 h-dibenzo[de,g]quinoléine-10,11-diol | |
US7732485B2 (en) | Treatment of cancer | |
EP3967692A1 (fr) | Polymorphisme cristallin d'un inhibiteur de pi3k et procédé de préparation associé | |
WO2022161263A1 (fr) | Inhibiteur de la voie de signalisation hedgehog de type nouveau | |
KR101992059B1 (ko) | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 | |
WO2023218245A1 (fr) | Composés dérivés d'hétéroaryle et composition pharmaceutique les comprenant | |
EP3967693A1 (fr) | Inhibiteur pi3k amorphe et composition pharmaceutique le comprenant | |
CN118355012A (zh) | 表现出癌细胞生长抑制效果的新型杂环取代嘧啶衍生物以及含有其的药物组合物 | |
WO2023218241A1 (fr) | Composés dérivés d'hétéroaryle et composition pharmaceutique les comprenant | |
HK40061155A (en) | Amorphous pi3k inhibitor and pharmaceutical composition comprising same | |
HK40061156A (en) | Crystal polymorphism of pi3k inhibitor and method for preparing same | |
HK40061214A (en) | Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer | |
HK40009120B (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10806962 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10806962 Country of ref document: EP Kind code of ref document: A1 |